Witkin Alison S, Channick Richard N
Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Bulfinch 148, Boston, MA, 02114, USA,
Curr Cardiol Rep. 2015 Aug;17(8):63. doi: 10.1007/s11886-015-0621-9.
Chronic thromboembolic pulmonary hypertension (CTEPH) occurs when a pulmonary embolism fails to undergo complete thrombolysis leading to vascular occlusion and pulmonary hypertension. Despite the fact that CTEPH is a potential consequence of pulmonary embolism, diagnosis requires a high degree of vigilance as many patients will not have a history of thromboembolic disease. The ventilation perfusion scan is used to evaluate for the possibility of CTEPH although right heart catheterization and pulmonary artery angiogram are needed to confirm the diagnosis. Pulmonary thromboendarterectomy is the first-line treatment for patients who are surgical candidates. Recently, riociguat has been approved for patients with nonsurgical disease or residual pulmonary hypertension despite surgical intervention. This review describes the pathophysiology, risk factors, diagnosis, and management of CTEPH.
慢性血栓栓塞性肺动脉高压(CTEPH)是在肺栓塞未能完全溶栓导致血管阻塞和肺动脉高压时发生的。尽管CTEPH是肺栓塞的潜在后果,但由于许多患者没有血栓栓塞性疾病史,因此诊断需要高度警惕。通气灌注扫描用于评估CTEPH的可能性,不过确诊需要右心导管检查和肺动脉造影。对于适合手术的患者,肺动脉血栓内膜剥脱术是一线治疗方法。最近,利奥西呱已被批准用于患有非手术性疾病或尽管进行了手术干预仍有残余肺动脉高压的患者。本综述描述了CTEPH的病理生理学、危险因素、诊断和管理。